BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, will participate in the TD Cowen 46th Annual Health Care Conference, taking place in Boston on March 3, including a fireside chat at 3:10 p.m. ET. An audio webcast of the fireside chat will be available at investors.amwell.com. About Amwell Amwell offers payers and health systems a single, comp ...

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on March 13, 2026 to holders of Common Shares of record on February 27, 2026. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash di ...

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce that it has been included in the TSX Venture 50 list. TSX Venture 50 is a ranking of the 50 top-performing companies on the TSX Venture Exchange over the last year. Companies are ranked based on three equally-weighted criteria of one-year share price appreciation, market capitalization increase, and Canadian consolidated trading value. Ravi Sood, Chief Executive O ...

HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced that it will be participating in SpareBank 1 Markets Energy Conference to be held in Oslo, Norway where Chief Executive Officer George Maxwell is scheduled to make a presentation on Wednesday, February 25, 2026. In conjunction with this press release, the Company has posted an updated investor presentation to its website. The presentation is available at the following link: (https://www ...

Core Viewpoint - Phillips Edison & Company, Inc. (PECO) has announced a public offering of $350 million in senior unsecured notes with a 4.750% interest rate, maturing in 2033, to support various corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at 99.920% of the principal amount and is expected to settle on February 26, 2026, pending customary closing conditions [1]. - The notes will be fully and unconditionally guaranteed by PECO [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including repaying borrowings under the revolving credit facility, term loans, acquiring additional properties, capital expenditures, and working capital [2]. Group 3: Underwriters - The offering is managed by a consortium of financial institutions including Wells Fargo Securities, BMO Capital Markets, and BofA Securities, among others [3]. Group 4: Company Overview - PECO is one of the largest owners and operators of grocery-anchored neighborhood shopping centers in the U.S., managing 324 shopping centers as of December 31, 2025, with a total of 33.5 million square feet across 31 states [6]. - The company focuses on creating grocery-anchored shopping experiences and improving communities [6].

Net Income per Diluted Share of $0.99 for the Fourth Quarter and $10.84 for the Full Year of 2025 Core FFO per Share of $1.40 for the Fourth Quarter and $6.68 for the Full Year of 2025 North America Same Property NOI increased by 7.9% for the Fourth Quarter and 5.7% for the Full Year of 2025 Acquired 14 MH and RV Communities for $457.0 million and Distributed Over $1.5 Billion of Capital to Shareholders, Inclusive of Cash Distributions and Share Repurchases in 2025 Establishing Guid ...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th A ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market open on March 3, 2026. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on March 3, 2026 (or 9:00 P.M. Singapore Time on March 3, 2026) to discuss the financial resul ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ("Inspired" or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 before the market opens on Tuesday, March 10, 2026. Inspired management will host a conference call and simultaneous webcast the same day at 8:30 a.m. ET / 12:30 p.m. in the UK to discuss the Company's resul ...

Core Insights - Cardiff Oncology reported positive results from the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a robust objective response rate (ORR) of 72.2% with the 30 mg onvansertib + FOLFIRI/bev combination, compared to 43.2% with standard of care (SoC) [1][5] - The trial also demonstrated a significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.37, indicating a strong potential for onvansertib to enhance patient outcomes [1][5] - The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data and plans expected in the first half of 2026 [1][2] Clinical Development - The CRDF-004 trial results indicate a consistent, dose-dependent treatment benefit, with nearly a 30% improvement in response rate over the control arm and encouraging durability trends in PFS [2][5] - The company has not observed significant added toxicity with the 30 mg onvansertib dose in combination with FOLFIRI/bev, supporting its advancement into registrational development [5] Financial Performance - For the year ended December 31, 2025, Cardiff Oncology reported total operating expenses of approximately $49.6 million, a slight increase from $49.3 million in 2024, primarily due to higher selling, general, and administrative expenses [8][14] - The company reported a net loss of $45.876 million for 2025, compared to a net loss of $45.455 million in 2024, with a net loss per common share of $0.69 [14] - As of December 31, 2025, Cardiff had approximately $58.3 million in cash and cash equivalents, sufficient to fund operations into the first quarter of 2027 [7] Leadership Changes - In January 2026, Cardiff announced executive leadership changes to support its transition into late-stage clinical development, appointing Mani Mohindru as interim Chief Executive Officer [4] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer to strengthen its leadership team [4]